Summary & Overview
HCPCS J7213: Ixinity (recombinant Factor IX) Injection, 1 i.u.
HCPCS Level II code J7213 designates an injection of recombinant coagulation factor IX, marketed as Ixinity, measured per 1 international unit. This code is used when administering factor IX replacement therapy for patients with hemophilia B, a nationally important therapy due to its high-cost biologic nature and role in preventing and treating bleeding episodes. Accurate coding of J7213 affects clinical care coordination, payer coverage determinations, and reimbursement for infusion services.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers approach coverage of recombinant factor IX products, typical sites where the service is delivered (hospital outpatient departments, ambulatory infusion centers, and physician offices), and common billing considerations tied to high-cost biologics.
Readers will find benchmarks related to utilization and reimbursement patterns, summaries of relevant payer policy themes, and clinical context about when recombinant factor IX therapy is indicated. Where specific input data is not provided, the report notes limitations such as missing associated taxonomies or ICD-10 details. This national-level summary is intended to support coding accuracy, payer engagement, and operational planning for organizations that bill for factor IX replacement therapy.
Billing Code Overview
HCPCS Level II code J7213 describes an injection of coagulation factor IX (recombinant), brand name Ixinity, billed per 1 international unit (i.u.). This service represents administration of a recombinant clotting factor used for treatment and prophylaxis in patients with hemophilia B (factor IX deficiency).
Service type: Injection — biologic replacement therapy
Typical site of service: Hospital outpatient department, ambulatory infusion center, or physician office with infusion capability
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a male adult with hemophilia B who requires episodic or scheduled replacement therapy with recombinant Factor IX (brand: Ixinity) to prevent or control bleeding. The patient presents to an outpatient infusion center, hospital outpatient department, or home health setting for administration of J7213 (Injection, coagulation factor IX (recombinant), ixinity, 1 i.u.). The clinical workflow includes verification of the physician order and weight-based dosing, review of recent bleeding history or planned invasive procedure, assessment of venous access, preparation of the exact number of international units (I.U.) required, identity and lot verification of the product, documentation of informed consent or treatment plan, administration via IV push or infusion per manufacturer guidance, monitoring for hypersensitivity or thromboembolic events during and after infusion, and documentation of units administered, lot number, expiration date, and patient response.
Common sites of service are:
-
Hospital outpatient infusion center
-
Ambulatory infusion clinic or specialty hemophilia treatment center
-
Home infusion administered by a trained nurse or self-administered by the patient when appropriate
Typical clinical indications include on-demand treatment of bleeding episodes, perioperative prophylaxis for invasive procedures, and routine prophylactic replacement in patients with congenital factor IX deficiency. Billing for J7213 is per international unit; accurate calculation of total units and use of appropriate modifiers and documentation are required for reimbursement and quality reporting.